Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 9, 2018
Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical TrialCorey Smith, Leone Beagley, Sweera Rehan, et al.The Journal of Clinical Investigation|August 5, 2020
Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiformeCorey Smith, Katie E Lineburg, J Paulo Martins, et al.The Journal of Experimental Medicine|June 23, 2010
Allelic polymorphism in the T cell receptor and its impact on immune responsesStephanie Gras, Zhenjun Chen, John J Miles, et al.Clinical & Translational Immunology|June 11, 2025
Allogeneic 'off-the-shelf' SARS-CoV-2-specific adoptive T-cell therapy for refractory viral infection and end organ diseaseAndrea S Henden, Katie E Lineburg, Archana Panikkar, et al.Plos Pathogens|February 14, 2022
SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variantsArchana Panikkar, Katie E Lineburg, Jyothy Raju, et al.Nature Communications|October 27, 2022
Ablation of CD8<sup>+</sup> T cell recognition of an immunodominant epitope in SARS-CoV-2 Omicron variants BA.1, BA.2 and BA.3Srividhya Swaminathan, Katie E Lineburg, Archana Panikkar, et al.Microbiology Spectrum|February 24, 2022
Limited Recognition of Highly Conserved Regions of SARS-CoV-2Srividhya Swaminathan, Katie E Lineburg, George R Ambalathingal, et al.Journal of Immunology (Baltimore, Md. : 1950)|June 11, 2013
HLA peptide length preferences control CD8+ T cell responsesMelissa J Rist, Alex Theodossis, Nathan P Croft, et al.Oncoimmunology|March 28, 2017
Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical responseCorey Smith, Victor Lee, Andrea Schuessler, et al.JCI Insight|November 16, 2018
Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosisMichael P Pender, Peter A Csurhes, Corey Smith, et al.Pageof 4